Crisaborole Powder CAS 906673-24-3 Raw Material

CAS: 906673-24-3

MF:  C14H10BNO3

MW: 251.05

EINECS: N/A

Specification​: 99% min Crisaborole 

Sample: Crisaborole  Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Crisaborole Powder Usage and Synthesis.

Crisaborole Powder (AN2728) is a non-steroidal phosphodiesterase 4 (PDE-4) inhibitor. Crisaborole CAS 906673-24-3 is used for the topical treatment of mild to moderate atopic dermatitis in patients over 2 years of age. Crisaborole Raw Material is the first topical dermatologic drug to enter the list of clinically urgent new drugs.

The biggest advantage of Crisaborole is that it is a small molecule non-hormonal drug that offers a combination of therapeutic effect and comfort, even with almost no side effects for some patients. It is the first topical dermatological drug to enter the list of new drugs in urgent clinical need. It can be said that the launch of Crisaborole fills the need for treatment of atopic dermatitis in children and adults in China and breaks the status quo of no new product in the field of topical non-hormonal anti-inflammatory for more than 10 years, which is of epoch-making significance.

Uses and functions of Crisaborole Powder.

In July 2020, Crisaborole Powder was approved for marketing in China, making it the first and only hormone-free PDE-4 inhibitor topical prescription drug for the treatment of mild to moderate atopic dermatitis in children and adult patients aged 2 years and above.

PDE4 is an inhibitor of phosphodiesterase 4 (PDE4), an enzyme involved in the control of inflammatory cell activity. PDE4 participates in the production of inflammatory factors such as IL-4/5/10/13 and prostaglandin PGE2 in inflammatory cells by controlling the degradation of cyclic adenosine monophosphate, and works by inhibiting PDE4 activity to improve the inflammatory response of the body.

Clinical studies have shown that in patients aged 2-79 years with mild to moderate atopic dermatitis, 28 days of treatment with clitoriborol resulted in significant relief and complete or almost complete resolution of the rash compared to placebo.

Sales of clitoriborol of $67 million in 2017;

With global sales of $147 million in 2018 and a growth rate of 119.40%, clitoriborol offers new hope for many patients with atopic dermatitis.

AN2728 shows potent activity in vivo and in vitro and is being investigated for its anti-inflammatory properties. It is also used as a pharmaceutical intermediate.

Crisaborole (AN2728) is a selective small molecule PDE4 inhibitor with broad-spectrum anti-inflammatory activity.